SYROS PHARMACEUTICALS INC (SYRS) Fundamental Analysis & Valuation

NASDAQ:SYRS ā€¢ US87184Q2066

Current stock price

0.1172 USD
-0.01 (-8.44%)
At close:
0.1072 USD
-0.01 (-8.53%)
After Hours:

This SYRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SYRS Profitability Analysis

1.1 Basic Checks

  • SYRS had negative earnings in the past year.
  • SYRS had a negative operating cash flow in the past year.
  • In the past 5 years SYRS always reported negative net income.
  • SYRS had a negative operating cash flow in each of the past 5 years.
SYRS Yearly Net Income VS EBIT VS OCF VS FCFSYRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

  • SYRS's Return On Assets of -115.08% is on the low side compared to the rest of the industry. SYRS is outperformed by 78.77% of its industry peers.
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
SYRS Yearly ROA, ROE, ROICSYRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SYRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRS Yearly Profit, Operating, Gross MarginsSYRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SYRS Health Analysis

2.1 Basic Checks

  • SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SYRS has more shares outstanding
  • Compared to 1 year ago, SYRS has a worse debt to assets ratio.
SYRS Yearly Shares OutstandingSYRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
SYRS Yearly Total Debt VS Total AssetsSYRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -16.26, we must say that SYRS is in the distress zone and has some risk of bankruptcy.
  • SYRS's Altman-Z score of -16.26 is on the low side compared to the rest of the industry. SYRS is outperformed by 82.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.26
ROIC/WACCN/A
WACC9.28%
SYRS Yearly LT Debt VS Equity VS FCFSYRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 2.25 indicates that SYRS has no problem at all paying its short term obligations.
  • SYRS has a worse Current ratio (2.25) than 72.98% of its industry peers.
  • SYRS has a Quick Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
  • SYRS's Quick ratio of 2.25 is on the low side compared to the rest of the industry. SYRS is outperformed by 71.23% of its industry peers.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.25
SYRS Yearly Current Assets VS Current LiabilitesSYRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SYRS Growth Analysis

3.1 Past

  • SYRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.20%, which is quite good.
  • Looking at the last year, SYRS shows a very negative growth in Revenue. The Revenue has decreased by -95.61% in the last year.
  • SYRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.12% yearly.
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%

3.2 Future

  • SYRS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.05% yearly.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y73.44%
EPS Next 2Y35.34%
EPS Next 3Y23.72%
EPS Next 5Y7.05%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-47.5%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SYRS Yearly Revenue VS EstimatesSYRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2031 2032 5M 10M 15M 20M
SYRS Yearly EPS VS EstimatesSYRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

1

4. SYRS Valuation Analysis

4.1 Price/Earnings Ratio

  • SYRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SYRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRS Price Earnings VS Forward Price EarningsSYRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRS Per share dataSYRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SYRS's earnings are expected to grow with 23.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.34%
EPS Next 3Y23.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SYRS Dividend Analysis

5.1 Amount

  • SYRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SYRS Fundamentals: All Metrics, Ratios and Statistics

SYROS PHARMACEUTICALS INC

NASDAQ:SYRS (3/19/2025, 8:16:43 PM)

After market: 0.1072 -0.01 (-8.53%)

0.1172

-0.01 (-8.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-12
Inst Owners24.37%
Inst Owner Change0%
Ins Owners0.78%
Ins Owner Change0%
Market Cap3.14M
Revenue(TTM)386.00K
Net Income(TTM)-97.81M
Analysts77.78
Price Target10.71 (9038.23%)
Short Float %0.18%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.44%
Min EPS beat(2)24.66%
Max EPS beat(2)78.21%
EPS beat(4)3
Avg EPS beat(4)26.22%
Min EPS beat(4)-86.73%
Max EPS beat(4)88.72%
EPS beat(8)5
Avg EPS beat(8)22.54%
EPS beat(12)8
Avg EPS beat(12)17.39%
EPS beat(16)11
Avg EPS beat(16)15.77%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-95.26%
Min Revenue beat(4)-100%
Max Revenue beat(4)-81.03%
Revenue beat(8)0
Avg Revenue beat(8)-67.21%
Revenue beat(12)3
Avg Revenue beat(12)-38.68%
Revenue beat(16)7
Avg Revenue beat(16)-14.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.7%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)4.86%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0.01
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 2.25
Altman-Z -16.26
F-Score0
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)31.74%
Cap/Depr(5y)133.96%
Cap/Sales(3y)5.46%
Cap/Sales(5y)135.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
EPS Next Y73.44%
EPS Next 2Y35.34%
EPS Next 3Y23.72%
EPS Next 5Y7.05%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-47.5%
Revenue Next 5Y-14.87%
EBIT growth 1Y17.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13%
OCF growth 3YN/A
OCF growth 5YN/A

SYROS PHARMACEUTICALS INC / SYRS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SYROS PHARMACEUTICALS INC (SYRS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SYRS.


What is the valuation status of SYROS PHARMACEUTICALS INC (SYRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to SYROS PHARMACEUTICALS INC (SYRS). This can be considered as Overvalued.


What is the profitability of SYRS stock?

SYROS PHARMACEUTICALS INC (SYRS) has a profitability rating of 0 / 10.


Can you provide the financial health for SYRS stock?

The financial health rating of SYROS PHARMACEUTICALS INC (SYRS) is 2 / 10.